MITQ shares climbed 6.5% this week to $0.64 while short interest swung wildly — up 30% day-over-day to 93,157 shares (0.94% of float) after collapsing 59% over the prior week. Borrowing costs fell 55% in a week to 0.78% while utilization jumped to 15.6%, still far below the 52-week peak of 97.7%.
Moving iMage Technologies closed at $0.64 on April 24, gaining 5.1% on the day and 6.5% across the week. The one-month chart shows a 7.8% advance. The stock operates without options and lacks analyst coverage, typical for sub-$10M names in cinema technology services.
Short interest hit 93,157 shares on April 23, representing 0.94% of the free float. That figure jumped 30% from the prior session's 71,798 shares but sits 59% below the week-ago level of 229,486 shares recorded April 15. The month-ago baseline was just 7,866 shares, putting the current level up 1,084% over 30 days.
The intraday surge on April 23 pushed shares short to a three-week high. The April 15 reading of 229,486 shares remains the clear outlier in the recent history — utilization that day touched 39.2%, more than double today's 15.6%. FINRA's fortnight settlement data from April 15 reported 211,670 shares short with one day to cover.
Cost to borrow dropped sharply from a 1.74% peak on April 15 to 0.78% as of April 23, down 55% week-over-week. The 30-day trend is still positive at +55%, reflecting the mid-March floor near 0.50%. Utilization climbed from 11.1% on April 22 to 15.6%, the highest since the April 15 spike. The 52-week high of 97.7% last visited in mid-2025 suggests substantial capacity remains.
Days to cover sits at one session per the official filing, consistent with the stock's thin trading volumes.
Enterprise value stood at $5.4M as of year-end 2025. The dividend score ranks in the 33rd percentile, sector score in the 20th. ORTEX short score sits at 34, placing the name in the 52nd percentile — neutral positioning. Days-to-cover ranks at the 64th percentile, utilization at the 41st.
President and CEO Philip Rafnson holds 2.07M shares (20.9% of the company), unchanged in the latest filing dated February 17. Bevan Wright holds 635,185 shares (6.4%), also flat. Founder Jose Delgado maintains 461,917 shares (4.6%).
Francois Godfrey added 125,000 shares in the period ending February 17, bringing his stake to 1.26% of the company. Renaissance Technologies increased its position by 21,100 shares to 117,300 (1.18%) as of year-end 2025. Katherine Crothall added 2,959 shares to 38,684, Scott Anderson added 2,307 to 32,748.
Two Sigma Securities grew its position by 16,417 shares to 27,104, XTX Markets added 12,906 to 25,979. Passive giants Vanguard (154,977 shares, 1.56%) and State Street (22,685 shares, 0.23%) held flat.
The most recent insider transaction dates to February 28, 2024 — founder Jose Delgado sold 49,586 shares at $0.667 for $33,074. That sale represents the 90-day net position. Prior activity includes director Katherine Crothall buying 900 shares at $0.80 in September 2023, CEO Rafnson purchasing 41,700 shares at $1.20 in May 2022, and Delgado buying 10,000 shares at $1.25 the same month.
The Delgado sale occurred at roughly the current price level — shares have oscillated around $0.65 for over two years.
Earnings are scheduled for May 15 at 4:30 PM ET. The stock reported on February 12 earlier this year; historical earnings dates lack price-reaction data in the snapshot. With no analyst estimates and negligible trading volumes, moves tend to be erratic around catalysts.
The short interest volatility — particularly the April 15 spike to 229,486 shares and subsequent collapse — suggests episodic position-taking rather than sustained conviction. Borrowing remains cheap and shares plentiful. Watch whether utilization can sustain above 15% or retreats to the sub-5% baseline seen through most of March.
See the live data behind this article on ORTEX.
Open MITQ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
